01:32 , Oct 14, 2015 |  BC Extra  |  Financial News

Audentes raises $65 million in series C

Gene therapy company Audentes Therapeutics Inc. (San Francisco, Calif.) raised $65 million in a series C round co-led by existing investor Sofinnova Ventures and new investor Redmile Group. New investors RA Capital; T. Rowe Price;...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

Cadiogen, Audentes Therapeutics deal

Audentes acquired fellow rare disease company Cardiogen for an undisclosed amount. Audentes gains AT003 (formerly CASQ2-CPVT ), a preclinical adeno-associated virus (AAV) vector-based therapy that delivers calsequestrin 2 (CASQ2) to cardiomyocytes to treat catecholaminergic polymorphic...